Alligator Bioscience AB (7AL0)

Overview

Alligator Bioscience AB (publ) operates as a research-oriented biotechnology entity, focusing primarily on the creation of antibody-based therapeutics aimed at combating cancer. Founded in the year 2000 and based in Lund, Sweden, the company endeavors to develop cutting-edge pharmaceuticals designed to address various forms of cancer through diligent research and innovation. This is facilitated through a range of proprietary technology platforms and strategic collaborations and licensing agreements with notable industry partners such as Aptevo Therapeutics, Inc., Orion Corporation, MacroGenics, Inc., Biotheus Inc., BioArctic AB, and Abclon Inc. These alliances not only expedite the development of their products but also enhance their market penetration and therapeutic impact.

Products and Services

• Mitazalimab: A phase 2 clinical trial candidate, Mitazalimab is a stimulatory antibody targeting CD40. It is being investigated for its therapeutic potential in treating solid metastatic tumors, including pancreatic cancer. The objective is to activate the immune system to recognize and combat cancer cells more effectively.
• ATOR-4066: Currently in the preclinical stage, ATOR-4066 is a tumor-directed bispecific antibody. It is developed using the innovative Neo-X-Prime technology platform, aiming for targeted immunotherapy applications. This product exemplifies the company's efforts in creating highly specialized treatments tailored to the unique characteristics of cancerous tumors.
• ALG.APV-527: This bispecific antibody, targeting both the 4-1BB and 5T4 molecules, is undergoing phase 1 clinical trials. ALG.APV-527 is designed to engage and activate the immune system specifically against solid metastatic tumors. Its dual-target approach represents an intricate strategy to bolster the body’s natural defenses against cancer.
• ATOR-1017: In phase 1 clinical trial, ATOR-1017 is an immunostimulatory antibody focused on the treatment of metastatic cancer. This product highlights Alligator Bioscience’s commitment to advancing therapies that enhance the immune response against cancerous cells, presenting a novel avenue for metastatic disease management.
• Technology Platforms: Alligator Bioscience leverages several proprietary technology platforms to spearhead its research and product development. These include ALLIGATOR-GOLD, a comprehensive human antibody library; ALLIGATOR-FAB, tailored to increase the diversity and drug development properties of antibodies; FIND, a molecular evolution technology for optimization of proteins; and RUBY, a specialized format for creating bispecific antibodies. These platforms underpin the company's innovative product pipeline and its ability to address complex therapeutic needs in oncology.